Related Experiment Video

Updated: May 15, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K

Research progress on m6A and drug resistance in gastrointestinal tumors

Ziyi Xu1, Bo Sun1, Weizheng Wang1

  • 1Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.

Frontiers in Pharmacology
|May 13, 2025
PubMed

Insights

N6-methyladenosine (m6A) RNA modifications are crucial in gastrointestinal (GI) tumor progression and drug resistance. Targeting m6A offers new strategies to overcome resistance and improve treatment efficacy in GI cancers.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Gastrointestinal (GI) tumors are a major cause of cancer mortality globally.
  • Drug resistance remains a significant challenge in treating GI cancers.
  • N6-methyladenosine (m6A) RNA modification is increasingly recognized for its role in cancer.

Purpose of the Study:

  • To explore the biological functions of m6A modifications.
  • To investigate m6A-mediated drug resistance mechanisms in GI tumors.
  • To identify novel therapeutic targets for overcoming drug resistance in GI cancers.

Main Methods:

  • Review of current literature on m6A RNA modifications.
  • Analysis of the roles of m6A 'writers,' 'erasers,' and 'readers' in GI tumors.
  • Exploration of m6A's association with chemotherapy, targeted therapy, and immunotherapy resistance.

Main Results:

  • m6A modification influences gene expression, RNA processing, and stability.
  • m6A is closely linked to resistance mechanisms in various GI tumors.
  • Specific m6A regulators are implicated in therapeutic resistance.

Conclusions:

  • Understanding m6A's role provides insights into GI tumor drug resistance.
  • Targeting m6A pathways presents promising therapeutic strategies.
  • Further research is needed to address limitations and optimize treatments.
Keywords:
RNA modificationsdrug resistanceepigenetic alterationsgastrointestinal tumorsm6A

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

597
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K